The management of LES with neuromuscular drugs during anesthesia is influenced by the unique pathophysiology of the syndrome:
- Non-depolarizing NMBAs: Patients with LES may exhibit decreased sensitivity to non-depolarizing neuromuscular blockers due to the overall reduction in acetylcholine release. This insensitivity arises because these drugs block the action of acetylcholine at the muscle endplate, but in LES, the primary issue is already reduced acetylcholine availability.
- Depolarizing NMBAs (e.g., Succinylcholine): Similarly, LES patients may show less sensitivity to depolarizing agents. These agents work by mimicking acetylcholine and depolarizing the neuromuscular endplate, but due to the reduced release and therefore lower baseline stimulation of acetylcholine in LES, the usual effects of these drugs might be diminished.
Anesthesia management in LES requires careful consideration and typically involves lower doses of both depolarizing and non-depolarizing NMBAs. Monitoring techniques such as nerve stimulators may be particularly useful in these patients to assess the degree of neuromuscular blockade and ensure adequate muscle function is maintained throughout the procedure. This approach helps in avoiding both under-treatment and overtreatment with neuromuscular blocking agents.
| Feature | Myasthenia Gravis | Lambert-Eaton Syndrome |
|---|---|---|
| Autoimmune target | Postsynaptic acetylcholine receptors at the neuromuscular junction | Presynaptic voltage-gated calcium channels |
| Core defect | Fewer available receptors, impairing synaptic transmission | Reduced calcium influx, so substantially less acetylcholine is released |
| Effect of repeated activity | Weakness worsens with continued activity and improves with rest | Weakness improves with repeated use, known as facilitation |
| Incidence | 10–20 per million per year; prevalence 150–250 per million | About 3 per million annually; 50–60% of cases are cancer-associated, most often small cell lung cancer |
| Non-depolarizing blockers | Highly sensitive; use significantly reduced doses with close neuromuscular monitoring | Decreased sensitivity, since acetylcholine availability is already reduced |
| Depolarizing blockers | Resistance may require higher doses, but succinylcholine risks triggering a myasthenic crisis | Less sensitive, as the lower baseline acetylcholine release blunts the usual effect |
| Anticholinesterase response | — | Minimal response |
